Cargando…
CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50
CD24, a heavily glycosylated glycosylphosphatidylinositol–anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such anti‐phagocytic factors and the immune response with immune–checkpoint inhibitors (ICI) remains unexplored. We evaluated CD24 and CD47 tumor pr...
Autores principales: | Ozawa, Yuichi, Harutani, Yuhei, Oyanagi, Jun, Akamatsu, Hiroaki, Murakami, Eriko, Shibaki, Ryota, Hayata, Atsushi, Sugimoto, Takeya, Tanaka, Masanori, Takakura, Toshiaki, Furuta, Katsuyuki, Okuda, Yuka, Sato, Kouichi, Teraoka, Shunsuke, Ueda, Hiroki, Tokudome, Nahomi, Kitamura, Yuka, Fukuoka, Junya, Nakanishi, Masanori, Koh, Yasuhiro, Yamamoto, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780034/ https://www.ncbi.nlm.nih.gov/pubmed/33084148 http://dx.doi.org/10.1111/cas.14705 |
Ejemplares similares
-
Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019) -
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Ikeda, Mio, et al.
Publicado: (2021) -
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022) -
Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015) -
PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
por: Hirose, Takayuki, et al.
Publicado: (2017)